Oxford Brain Diagnostics Ltd.
Oxford Brain Diagnostics Ltd is rethinking how brain health is assessed and managed. Founded in neuropathological and neuroimaging expertise, the company’s patented Cortical Disarray Measurement (CDM) technology uses MRI brain scan data to support early and differential diagnosis, track progression, and predict the decline of neurodegenerative diseases. Oxford Brain Diagnostics is committed to assessing brain health based on changes in the cellular structure, supporting drug development, and helping clinicians around the world in their fight to defeat Alzheimer’s and other neurodegenerative diseases.
Company details
Find locations served, office locations
- Business Type:
- Technology
- Industry Type:
- Medical Monitoring
- Market Focus:
- Nationally (across the country)
Our Story
Founded in neuropathological expertise.
Our sophisticated diffusion analysis is based on neuropathology, and the correlations between microscopic data and MRI analysis. Based at the University of Oxford, Dr Steven Chance and Professor Mark Jenkinson combined their world class expertise to develop CDM® technology.
Today, this breakthrough technology can provide an assessment of brain health based on changes at the cellular level, for dementia patients, which previously could only be analysed at post-mortem.
Founded in neuropathological expertise.
Our sophisticated diffusion analysis is based on neuropathology, and the correlations between microscopic data and MRI analysis. Based at the University of Oxford, Dr Steven Chance and Professor Mark Jenkinson combined their world class expertise to develop CDM® technology.
Today, this breakthrough technology can provide an assessment of brain health based on changes at the cellular level, for dementia patients, which previously could only be analysed at post-mortem.
The Challenge
We are on a mission to change the way the world thinks about brain health.
Oxford Brain Diagnostics is committed to analysing the cellular structure of the brain in a way no one else can, to support drug development and aid clinicians around the world in their fight to defeat Alzheimer’s and other neurodegenerative diseases.
Our Solution
Our novel technology assesses brain health based on changes in the cellular structure.
- Our pioneering approach, and novel measures unlock unique insights that enable us to predict, detect, quantify, track and differentiate neurodegenerative diseases.
- This gives us the potential to revolutionise how people think about brain health and disease management.
Our Science
Supporting more efficient drug development and personalised patient care.
Previously inaccessible insights unlocked by our proprietary technology will support more targeted, efficient drug development.